CN Patent

CN114409653A — 一种桥环并嘧啶并环类化合物及其用途

Assigned to Suzhou Wentian Pharmaceutical Technology Co ltd · Expires 2022-04-29 · 4y expired

What this patent protects

本发明提供了一种桥环并嘧啶并环类化合物及其用途，桥环并嘧啶并环类化合物为下式(I)表示的化合物及其异构体或其药学上可接受的盐。本发明化合物能够应用于针对KRASG12C突变蛋白相关癌症的治疗药物中，KRASG12C突变蛋白相关癌症疾病选自：肺癌、结直肠癌、胰腺癌、胰腺癌、肝癌、胃癌、食道癌、胆管癌、乳腺癌、卵巢癌、子宫颈癌、黑色素瘤、脑胶质瘤、淋巴癌、白血病。

USPTO Abstract

本发明提供了一种桥环并嘧啶并环类化合物及其用途，桥环并嘧啶并环类化合物为下式(I)表示的化合物及其异构体或其药学上可接受的盐。本发明化合物能够应用于针对KRASG12C突变蛋白相关癌症的治疗药物中，KRASG12C突变蛋白相关癌症疾病选自：肺癌、结直肠癌、胰腺癌、胰腺癌、肝癌、胃癌、食道癌、胆管癌、乳腺癌、卵巢癌、子宫颈癌、黑色素瘤、脑胶质瘤、淋巴癌、白血病。

Drugs covered by this patent

Patent Metadata

Patent number
CN114409653A
Jurisdiction
CN
Classification
—
Expires
2022-04-29
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Wentian Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.